(NASDAQ: ACHN) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates.

Aimmune is a clinical-stage biopharmaceutical company developing proprietary product candidates and advancing a therapeutic approach for the treatment of peanut and other food allergies.

Apellis Pharmaceuticals (NASDAQ: APLS) is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

Avanir Pharmaceuticals (NASDAQ: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Avexis, a Novartis company, is dedicated to developing and commercializing gene therapies for patients and famiies devastated by rare and life-thretening neurological genetic diseases

Biohaven Pharma (NASDAQ: BHVN) is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.

BioPharmX focus is to develop products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal.

Ceptaris Therapeutics (acquired by Actelion) is a privately held specialty pharmaceutical company developing a product for the treatment of cutaneous T-cell lymphoma (CTCL)

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases.

CoLucid Pharmaceuticals is a biotechnology company focusing on therapies for central nervous system disorders.

CRISPR Therapeutics is a world leader in CRISPR Cas9 gene editing technology.

Cubist Pharmaceuticals was an American biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products.

Durata Therapeutics (NASDAQ: DRTX) is a pharmaceutical company focused on the development and commercialization of therapeutic solutions in infectious disease.

Dynavax Technologies (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

Foamix is working to solve some of today’s most difficult therapeutic challenges. With every problem we take on, our approach is the same: question traditional assumptions and find a better solution.

Intellia is revolutionizing medicine by harnessing the power of genome editing to develop potential cures.

Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everythingwe do, from early research to product development

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases.

Nexcida, a Frazier Healthcare Partners portfolio company, is developing novel antibiotics to treat serious, life-threatening bacterial infections.

Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine.

Ocera Therapeutics (NASDAQ: OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet clinical need.

OncoGenex Pharmaceuticals (NASDAQ: OGXI) is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

REGENXBIO (NASDAQ: RGNX) is a gene therapy platform company that is leveraging its proprietary NAV® Technology to advance the development of life-changing adeno-associated viral (AAV) treatments for lysosomal storage disorders, ocular diseases, and other unmet clinical needs.

Rempex Pharmaceuticals (Acquired by The Medicines Company) is a pharmaceutical company focused on the discovery and development of new antibacterial drugs to treat multi-drug resistant bacterial pathogens.

River Vision Development Corporation researches and develops protein therapies. The Company provides its products for the treatment of graves' orbitopathy.

Sagent Pharmaceuticals (NASDAQ: SGNT) is an international specialty injectable pharmaceutical company bringing finished pharmaceutical products to the U.S. market. Acquired by Nichi-Iko Pharmaceutical Co., Ltd.

Strongbridge Biopharma plc (NASDAQ: SBBP) is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics.

Tokai Pharmaceuticals (NASDAQ: TKAI), based in Boston, Massachusetts, is focused on translating innovative science to develop and deliver innovative therapies that provide hope and healing for patients living with cancer.

Tranzyme Pharma (NASDAQ:TZYM) is developing novel GI therapeutics.

Trevena is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System (CNS) conditions.

Vicept Therapeutics is developing novel products for the treatment of rosacea and other dermatological conditions. Acquired by Allergan.

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. Acquired by Shire

YM BioSciences (NYSE: YMI) is a pharmaceutical company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. Acquired by Gilead Sciences.

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microneedle, or ADAM technology.